The 50 most recent market catalysts affecting $MRNA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Bearish
Impact 55
Jefferies Adjusts Price Target on Moderna to $215
Jefferies, a prominent investment bank, has reduced its price target for Moderna (MRNA) from $230 to $215. This action signals a revised, less favorable valuation outlook for the b…
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 65
JPMorgan Adjusts Price Target on Moderna to $102 From $77
JPMorgan, a prominent financial institution, has raised its price target for Moderna from $77 to $102. This significant upgrade signals increased confidence from a major analyst in…
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 75
Morgan Stanley Adjusts Price Target on Moderna to $200 From $95
Morgan Stanley has updated its financial outlook for Moderna, Inc., raising its price target from $95 to $200. This is a significant upward revision, suggesting a strong positive r…
Nov 17, 2026
Corporate Catalyst
Neutral
Impact 55
Moderna Officer Proposes Sale of Approximately $8.6 Million in Common Stock
Moderna officer Stephen Hoge has disclosed an intent to sell 39,160 shares of MRNA common stock, valued at approximately $8.6 million. This proposed sale follows previous transacti…
Nov 12, 2026
Corporate Catalyst
Neutral
Impact 75
Moderna and Merck Advance Commercialization Plans for Intismeran
Moderna and Merck are moving forward with concrete plans for the commercialization of intismeran, their individualized neoantigen therapy. This involves defining co-promotion strat…
Nov 12, 2026
Corporate Catalyst
Bullish
Impact 65
Argus Adjusts Price Target on Moderna to $280 From $180
Argus Research announced a substantial increase in its price target for Moderna, raising it from $180 to $280. This analyst action reflects a more bullish outlook on Moderna's futu…
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 65
Moderna Announces Publication of Real-World Study on mNEXSPIKE Effectiveness
Moderna's 8-K filing highlights the publication of a real-world study showing its mNEXSPIKE vaccine has a 35.9% relative vaccine effectiveness against medically attended COVID-19 a…
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 65
Piper Sandler Adjusts Price Target on Moderna
On November 9, 2026, Piper Sandler significantly raised its price target for Moderna (MRNA) from $230 to $305. This upward revision reflects a more favorable valuation outlook by t…
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 92
Moderna Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Outlook
Moderna's Q3 2026 earnings report shows a 29% revenue increase and a GAAP net income of $0.2 billion, significantly outperforming analyst expectations. This strong performance, pri…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 75
Moderna Receives Canadian Authorization for Seasonal Influenza and Combination Vaccines
Moderna has secured Canadian authorization for its mFLUSIVA (seasonal flu) and mCOFLU (combo flu/COVID) vaccines, representing the first global approvals for these specific mRNA pr…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 55
WHO Advisory Group Recommends Advancing Moderna's mRNA-1469 Vaccine to Phase 2/3 Efficacy Study
Moderna announced that the WHO's Technical Advisory Group has recommended its mRNA-1469 vaccine candidate for Bundibugyo virus disease to proceed to a Phase 2/3 efficacy study. Thi…
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 65
Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 ASH Annual Meeting
Moderna announced that initial clinical data for its investigational multiplexed mRNA therapeutic, mRNA-2808, will be presented at the 2026 ASH Annual Meeting. This is significant …
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 65
Moderna CEO Discusses Potential 2028 Launch for Skin Cancer Vaccine in Europe
Moderna's CEO has publicly stated a target of 2028 for the European market launch of its mRNA-based skin cancer vaccine. This announcement is significant as it provides a concrete …
Oct 29, 2026
Corporate Catalyst
Bearish
Impact 85
Law Firm Announces Investigation into Moderna, Inc. Following Clinical Trial Data Leak
A law firm has announced an investigation into Moderna after clinical trial results for a joint cancer vaccine with Merck were prematurely leaked, causing Moderna's stock to drop o…
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 65
Piper Sandler Adjusts Price Target on Moderna to $230 From $167
Piper Sandler, a notable investment bank, has significantly raised its price target for Moderna (MRNA) from $167 to $230. This upward revision indicates a strengthened belief in Mo…
Oct 24, 2026
Corporate Catalyst
Neutral
Impact 85
Moderna and Merck Release Phase 3 Data for Cancer Vaccine Candidate Intismeran Autogene
Moderna and Merck disclosed highly positive topline results from their Phase 3 INTerpath-001 trial for intismeran autogene, an individualized mRNA cancer therapy. The combination t…
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 85
Moderna and Merck Report Phase 3 Results for Cancer Vaccine
Moderna and Merck have reported highly positive Phase 3 clinical trial results for their personalized cancer vaccine, intismeran autogene, combined with Merck's Keytruda. The study…
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 85
Moderna and Merck Report Phase 3 Results for Cancer Vaccine Combination
Moderna and Merck reported highly positive Phase 3 trial results for their individualized mRNA cancer vaccine in combination with Keytruda for resected stage IIB-IV melanoma. This …
Oct 22, 2026
Corporate Catalyst
Bearish
Impact 75
Moderna and Merck Shares Decline Following Potential Melanoma Vaccine Data Leak
Moderna and Merck experienced a share decline following reports of a potential data leak regarding their experimental therapeutic cancer vaccine. This event is significant because …
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 75
Moderna shares are trading higher after Goldman Sachs raised its price target on the stock from $120 to $137.
This headline indicates a positive sentiment shift from a major investment bank towards Moderna, which can significantly influence investor perception and trading behavior. The upg…
Oct 12, 2026
Market Technicals
Neutral
Impact 65
10 Health Care Stocks With Whale Alerts In Today’s Session
The filing details significant options trading activity, often indicative of 'whale' movements, across several health care stocks. This matters because large, unusual options trade…
Oct 9, 2026
Corporate Catalyst
Neutral
Impact 85
Moderna Stock Hits New 52-Week High: What's Happening?
Moderna's stock is experiencing a significant surge, reaching a new 52-week high, driven by two key factors. Firstly, its inclusion in the Nasdaq-100 Index, replacing Warner Bros. …
Oct 9, 2026
Corporate Catalyst
Bullish
Impact 75
Shares of vaccine stocks are trading higher following a New York Times report detailing a new public-private partnership involving the National Institutes of Health to accelerate cancer vaccine development.
The formation of a public-private partnership with the NIH to accelerate cancer vaccine development is a significant positive catalyst for the biotechnology sector. This collaborat…
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 75
Moderna shares are trading higher after Tempus announced an expanded collaboration with Merck and the company for potential commercialization of intismeran autogene. Also, Morgan Stanley raised its price target on the stock from $89 to $95.
The headline presents a clear positive catalyst for Moderna. The expanded collaboration with Tempus and Merck for a potential commercialization of intismeran autogene suggests a pr…
Oct 6, 2026
Geopolitical Risk
Bearish
Impact 75
Moderna shares are trading lower, possibly as the stocks sells of from recent strength related to a suspected pneumonic plague in Russia.
This headline demonstrates how geopolitical health concerns, even if unconfirmed, can trigger significant, albeit potentially short-lived, market reactions in specific sectors. The…
Oct 2, 2026
Market Technicals
Neutral
Impact 65
Reported Earlier, Moderna To Replace Warner Bros. Discovery In Nasdaq-100 Index Before Market Open On October 9, 2026
This headline signifies a significant technical rebalancing within the Nasdaq-100 index. Moderna (MRNA) will experience a boost from passive index funds that are mandated to hold i…
Oct 1, 2026
Corporate Catalyst
Bearish
Impact 75
Moderna Stock Is Trending: What's Going On?
Moderna (MRNA) shares have seen a sharp rally recently due to positive late-stage trial data for its experimental cancer vaccine. However, this momentum has been challenged by a be…
Sep 30, 2026
Market Technicals
Bullish
Impact 55
Moderna Shares Reverse Weakness, Rise Over 3% After Key Trading Signal
The filing highlights a 'Power Inflow' signal for Moderna (MRNA) at 11:30 AM EST on September 30, at a price of $186.46, following an initial 5% decline. This signal, generated by …
Sep 30, 2026
Corporate Catalyst
Bearish
Impact 60
What's Going On With Moderna Stock on Wednesday?
Moderna's announcement of a new Chief Operating Officer, Juan Andres, and the retirement of its Chief Technical Operations and Quality Officer, Jerh Collins, signals a strategic re…
Sep 30, 2026
Corporate Catalyst
Bearish
Impact 75
Moderna shares are trading lower after Citigroup downgraded the stock from Neutral to Sell. The company appointed Juan Andres as COO.
The Citigroup downgrade from Neutral to Sell is a significant negative catalyst for Moderna, directly impacting its stock price. Analyst downgrades often lead to immediate selling …
Sep 30, 2026
Corporate Catalyst
Neutral
Impact 55
Moderna Announces Appointment Of Juan Andres As COO Effective October 5
The appointment of a Chief Operating Officer (COO) at Moderna is a corporate governance event. While not directly impacting financial results in the short term, a strong COO can im…
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 75
Moderna Sets Another Fresh 52-Week High: What's Happening?
Moderna (MRNA) shares have surged to a new 52-week high of $208.90, driven by news that its experimental cancer drug, intismeran autogene, will be prominently featured at the Europ…
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 75
Moderna Stock Reached New 52-Week High: What's Happening?
Moderna's stock surge is directly linked to the upcoming presentation of late-stage clinical trial results for its cancer treatment, intismeran autogene, at the ESMO Congress. This…
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 75
Why is Moderna (MRNA) Stock Trending After Hours?
Moderna (MRNA) shares are trending and saw a significant jump in the regular session, continuing into after-hours, due to the announcement that three abstracts on its investigation…
Sep 21, 2026
Macro/Central Bank
Neutral
Impact 65
'White House Drafting Executive Order To Take Over NIH Grant Approvals' - The Hill
The White House is reportedly drafting an executive order that would give it more oversight of the NIH's grant approval process. This is significant because the NIH is a primary so…
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 75
Moderna shares are trading higher. The company announced three abstracts on its mRNA-based individualized neoantigen therapy intismeran autogene have been accepted for presentation at the ESMO Congress 2026.
This news is a significant positive catalyst for Moderna. The acceptance of abstracts for a major medical conference like ESMO 2026 indicates that their individualized neoantigen t…
Sep 21, 2026
Market Technicals
Neutral
Impact 65
10 Health Care Stocks Whale Activity In Today’s Session
The filing highlights unusual options activity, often indicative of large investors ('whales') taking significant positions. This matters because such activity can precede notable …
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 55
Moderna To Present Three Abstracts On Intismeran Autogene At European Society For Medical Oncology Congress 2026
Moderna announced the acceptance of three abstracts for presentation at the European Society for Medical Oncology (ESMO) Congress in October 2026. These abstracts concern intismera…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 92
Moderna Stock Is Surging: What's Going On?
Moderna's stock has surged over 100% in the past month, primarily due to the announcement on August 19th of successful Phase 3 results for its individualized cancer vaccine, intism…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 85
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
Moderna's stock experienced a massive surge, more than doubling in a month, after announcing positive Phase 3 results for its personalized mRNA cancer vaccine in melanoma, develope…
Sep 3, 2026
Corporate Catalyst
Bearish
Impact 75
Moderna shares are trading lower after Rothschild & Co downgraded the stock from Neutral to Sell.
The downgrade by Rothschild & Co from Neutral to Sell is a significant negative catalyst for Moderna. Analyst downgrades, especially from a 'Neutral' to 'Sell' rating, often signal…
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 65
Moderna Stock Moves Lower Wednesday: What's Going On?
Moderna's stock is seeing a dip following a substantial 170% surge over the past month. This pullback is attributed to traders balancing recent positive news, such as a landmark on…
Sep 1, 2026
Corporate Catalyst
Neutral
Impact 75
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
This filing highlights the significant positive Phase 3 results for Moderna and Merck's personalized mRNA cancer vaccine, a major breakthrough as the first mRNA-based cancer therap…
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 65
This Moderna Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
The filing highlights analyst upgrades for three distinct companies, with Moderna (MRNA) being the primary focus. Argus Research upgraded MRNA from Hold to Buy and set a $180 price…
Aug 28, 2026
Corporate Catalyst
Bearish
Impact 75
Moderna shares are trading lower after the company announced the pricing of its upsized $2.6 billion offering of Convertible Senior Notes.
The pricing of a $2.6 billion upsized convertible senior notes offering by Moderna is a significant corporate catalyst. While convertible notes offer a lower interest rate than tra…
Aug 27, 2026
Corporate Catalyst
Bullish
Impact 75
Moderna Says FDA Approved sBLAs For 2026-2027 Spikevax And mNEXSPIKE Formulas Targeting JN.1-Lineage XFG Subvariant; Says Vaccines Expected Available In Coming Days
Moderna's FDA approval for its updated Spikevax and mNEXSPIKE formulas targeting the JN.1-lineage XFG subvariant is a significant positive for the company, securing its position fo…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.